Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epi-RCHOP
2024-515846-18-00Phase 2Authorised
- Sponsor
- LYSARC
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of tazemetostat in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (2 cohorts), sponsored by LYSARC. Primary endpoint: Dose-limiting toxicity incidence and severity. Planned start Sep 2016; status: authorised.
02
Drugs
tazemetostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2024-515846-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515846-18-00.